Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607082 · ClinicalTrials.gov registry record · NA
COVID-19 Bivalent Booster Megastudy
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 2,600,000
- Enrollment target
NCT05607082: Completed NA study, sponsored by University of Pennsylvania.
NCT05607082 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 2,600,000 participants, above the 1,359-participant average among 58,714 other NA trials with a reported enrollment target (191217% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607082, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,600,000 participants
- Enrollment target
Study Summary
This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only receive the usual communications from their partner organization) to identify which interventions significantly increase vaccination rates. Pharmacy customers will be randomly assigned to receive one of the interventions designed by team scientists to encourage vaccination or to a control group. The baseline intervention will be based on the top-performing SMS intervention identified in the investigators previous megastudies on encouraging vaccination (Milkman et al., 2021b, 2022). Pharmacy customers will receive SMS messages conveying that a COVID booster vaccine is reserved or waiting for them at the pharmacy. Additional behavioral science messaging strategies will be tested by building off of this baseline intervention.
Primary Outcome
Whether patients receive a bivalent COVID booster at the pharmacy in question
Interventions
- BEHAVIORAL COVID Booster text messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,600,000 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2023-02-06 |
| Phase | NA |
What the finished NCT05607082 record still lists
NCT05607082 is an interventional study that assigns participants to a tested intervention. Its 2,600,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,359-participant average among 58,714 other NA trials with a reported enrollment target (191217% higher).
The record links to 0 conditions, and to 1 intervention - of which COVID Booster text messages is the first listed.
NCT05607082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05607082 about?
NCT05607082 is a clinical study titled "COVID-19 Bivalent Booster Megastudy". This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only re...
What is the current status of trial NCT05607082?
This trial is currently completed. It is a NA study. The enrollment target is 2,600,000 participants. The study started on 2022-11-03. Estimated completion is 2023-02-06.
What interventions are being tested in trial NCT05607082?
The interventions under investigation include: COVID Booster text messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT05607082?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05607082's enrollment target sits among peer trials
2,600,000 1st of 2000 higher than 2,000 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI